Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-05-04
2000-10-31
Stockton, Laura L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514323, 514411, 514374, 514397, 514381, 546200, 5462767, 548238, 548252, 5483114, 548444, A61K 314439, C07D40112
Patent
active
061403520
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INVENTION
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta..sub.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.
BACKGROUND OF THE INVENTION
The current preferred treatment for Type II, non-insulin dependent diabetes as well as obesity is diet and exercise, with a view toward weight reduction and improved insulin sensitivity. Patient compliance, however, is usually poor. There are no currently approved medications that adequately treat either Type II diabetes or obesity. The invention described herein is directed toward an effective and timely treatment for these serious diseases.
One therapeutic opportunity that has been recently recognized involves the relationship between adrenergic receptor stimulation, anti-hyperglycemic effects, and metabolic events such as increased basil metabolic rate. Compounds that act as .beta..sub.3 adrenergic receptor agonists have been shown to exhibit a marked effect on lipolysis, thermogenesis, and serum glucose levels in animal models of Type II (non-insulin dependent) diabetes.
The .beta..sub.3 receptor, which is found in several types of human tissue including human fat tissue, has roughly 50% homology to the .beta..sub.1 and .beta..sub.2 receptor subtypes yet is considerably less abundant. The importance of the .beta..sub.3 receptor is a relatively recent discovery since the amino-acid sequence of the human receptor was only elucidated in the late 1980's. A large number of publications have appeared in recent years reporting success in discovery of agents that stimulate the .beta..sub.3 receptor. Despite these recent developments there remains a need to develop a selective .beta..sub.3 receptor agonist which has minimal agonist activity against the .beta..sub.1 and .beta..sub.2 receptors.
The present invention provides methods of treating Type II diabetes, treating obesity, and stimulating the .beta..sub.3 receptor. In addition, the present invention also provides novel compounds that are selective .beta..sub.3 receptor agonists and as such are useful for treating Type II diabetes, obesity, and stimulating the .beta..sub.3 receptor. U.S. Pat. No. 4,503,067 discloses carbazolyl-(4)-oxypropanolamine compounds, some of which are within the scope of formula I, as .beta.-adrenoceptor antagonists and vasodilators.
SUMMARY OF INVENTION
The present invention provides methods of treating Type II diabetes, treating obesity, and stimulating the .beta..sub.3 receptor which comprise administering to a patient in need thereof a compound described in Formula I below. ##STR2## wherein: X.sub.1 is --OCH.sub.2 --, --SCH.sub.2 --, or a bond; ##STR3## the A.sub.1 groups are independently carbon or nitrogen, provided that no more than 2 nitrogens may be contained in either fused 6 membered ring and those 2 nitrogens may not be adjacent; the group consisting of: ##STR4## R.sub.5 is hydrogen or C.sub.1 -C.sub.4 alkyl; R.sub.6 is hydrogen, C.sub.1 -C.sub.4 alkyl, or CO.sub.2 (C.sub.1 -C.sub.4 alkyl); form a C.sub.3 -C.sub.6 cycloalkyl; to form a C.sub.3 -C.sub.8 cycloalkyl; attached to form: ##STR5## provided that R.sub.5 is hydrogen; R.sub.7 is independently hydrogen, halo, hydroxy, OR.sub.2, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, aryl, COOR.sub.2, CONR.sub.2 R.sub.2, NHCOR.sub.2, C.sub.1 -C.sub.4 alkoxy, NHR.sub.2, SR.sub.2, CN, SO.sub.2 R.sub.2, SO.sub.2 NHR.sub.2, or SOR.sub.2 ; C.sub.1 -C.sub.4 haloalkyl, CO.sub.2 R.sub.2, CONR.sub.11 R.sub.12, CONH(C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy), SR.sub.2, CSNR.sub.2, CSNR.sub.11 R.sub.12, NR.sub.2 SO.sub.2 R.sub.2, SO.sub.2 R.sub.2, SO.sub.2 NR.sub.11 R.sub.12, SOR.sub.2, NR.sub.11 R.sub.12, optionally substituted aryl, optionally substituted heterocycle, or C.sub.2 -C.sub.4 alkenyl substituted with CN, CO.sub.2 R.sub.2 or CONR.sub.11 R.sub.12 ; (CH.sub.2).sub.n C.sub.3 -C.sub.8 cycloalkyl, (CH.sub.2).sub.n aryl, (CH.sub.2).sub.n heter
REFERENCES:
patent: 4032575 (1977-06-01), Ikezaki et al.
patent: 4140789 (1979-02-01), Jaeggi et al.
patent: 4235919 (1980-11-01), Berthold
patent: 4288452 (1981-09-01), Sombroek et al.
patent: 4309443 (1982-01-01), Smith et al.
patent: 4310527 (1982-01-01), Jaeggi et al.
patent: 4338333 (1982-07-01), Ainsworth et al.
patent: 4346093 (1982-08-01), Friebe et al.
patent: 4367235 (1983-01-01), Ross et al.
patent: 4385066 (1983-05-01), Ainsworth et al.
patent: 4391826 (1983-07-01), Mills et al.
patent: 4396627 (1983-08-01), Ainsworth et al.
patent: 4432993 (1984-02-01), Ferris
patent: 4478849 (1984-10-01), Ainsworth et al.
patent: 4497813 (1985-02-01), Ostermayer et al.
patent: 4503067 (1985-03-01), Wiedemann et al.
patent: 4513001 (1985-04-01), Joannic et al.
patent: 4636511 (1987-01-01), Ostermayer et al.
patent: 4652679 (1987-03-01), Alig et al.
patent: 4697022 (1987-09-01), Leinert
patent: 4727067 (1988-02-01), Ostermayer et al.
patent: 4751246 (1988-06-01), Philion
patent: 4772631 (1988-09-01), Holloway et al.
patent: 4892886 (1990-01-01), Alig et al.
patent: 4940800 (1990-07-01), Bertolini et al.
patent: 4960783 (1990-10-01), Bonse et al.
patent: 4977148 (1990-12-01), Holloway et al.
patent: 5013761 (1991-05-01), Beedle et al.
patent: 5064863 (1991-11-01), Alig et al.
patent: 5166218 (1992-11-01), Alig et al.
patent: 5254595 (1993-10-01), Guzzi et al.
patent: 5321036 (1994-06-01), Sher
patent: 5393772 (1995-02-01), Yue et al.
patent: 5420294 (1995-05-01), Beedle et al.
patent: 5453436 (1995-09-01), Ohlstein
patent: 5488151 (1996-01-01), Baroni et al.
patent: 5534640 (1996-07-01), Tegeler et al.
patent: 5541197 (1996-07-01), Fisher et al.
patent: 5541204 (1996-07-01), Sher et al.
patent: 5561142 (1996-10-01), Fisher et al.
patent: 5574164 (1996-11-01), Tegeler et al.
patent: 5776983 (1998-07-01), Washburn et al.
Neugebauer et al., CA 117:39731, 1992.
G. Neugebauer and P. Neubert "Metabolism of carvedilol in man" European Journal of Drug Metaboolism and Pharmacokinetics 16 (4) :257-260 (1991).
S. L. Heald, et al. "Synthesis of Iodine-125 labeled 14-(4-Azidobenzyl)Carazolol: A Potent Beta Adrenergic Photoaffinity Probe" J. Med. Chem. 26: (6) :832-838 (1983).
R. G. L. Shorr, et al. "The Beta-Adrenergic Receptor: Rapid Purification and Covalent Labeling by Photoaffinity Crosslinking" Proc. Natl. Acad. Sci. USA 79:2778-2782 (1982).
B. Ehmer, et al. "Influence of Carvedilol on Blood Glucose and Glycohaemoglobin A1 in Non-Insulin Dependent Diabetes" Drugs 36 (6) :136-140 (1988).
Tejani-Butt and Brunswick, "Synthesis an .beta.-Adrenergic Receptor Blocking Potency of 1-(Substituted amino)-3-(4-indolyloxy)propan-2-ols" J. Med. Chem 29:1524-1527 (1986).
Burgisser, et al. "Alternative Explanation for the Apparent `Two-Step` Binding Kinetics of High-Affinity Racemic Antagonist Radioligands" Molecular Pharmacology 19:509-512 (1981).
Marinetti, et al. "Beta-Adrenergic Receptors of Human Leukocytes" Biochemical Pharmacology 32(13):2033-2043 (1983).
Howe, et al. "Selective b3-adrenergic agonists of brown adipose tissue and thermogenesis" Chemical Abstracts 117: 40209r (1992).
Jimenez, et al. "1-Thymoxy-2-propanolamines" Chemical Abstracts 86:29468v (1977).
Izquierdo Sanjose, et al. "Morpholine derivative and its salts" Chemical Abstracts 90:186971d (1979).
Crowell Thomas A.
Evrard Deborah A.
Jones Charles D.
Muehl Brian S.
Rito Christopher J.
Eli Lilly and Company
Stockton Laura L.
Voy Gilbert T.
LandOfFree
Carbazolyl-substituted ethanolamines as selective .beta.-.sub.3 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbazolyl-substituted ethanolamines as selective .beta.-.sub.3 , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbazolyl-substituted ethanolamines as selective .beta.-.sub.3 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2052242